Table I:

Serum Paraoxonase, Arylesterase, or Lactonase activities of PON1 in mild cognitive impairment (MCI) or Alzheimer’s disease (AD) patients as reported in selected studies.

Study-PON1 activities (n)	AD	MCI
- Saeidi et al. 2017 (n=150)20
Paraoxonase	↓
Arylesterase	↓
- Bednarska-Makaruk et al. 2017 (n=425)*67
Arylesterase	↔	↔
- Castellazzi et al. 2016 (n=724)*48
Paraoxonase	↔	↔
Arylesterase	↓	↓
- Arslan et al. 2016 (n=50)68
Paraoxonase	↓
- Alam et al. 2014 (n=241)17
Paraoxonase	↔
- Bacchetti et al. 2015 (n=83)18
Paraoxonase	↓
Arylesterase	↓
- Cervellati et al. 2015 (n=593)*52
Paraoxonase	↔	↔
Arylesterase	↓	↓
- Wehr et al. 2009 (n=226)*53
Paraoxonase	↔	↔
- Bednarska-Makaruk et al. 2013 (n=433)69
Arylesterase	↓
Erlich et al. 2012 (n=632)19
Arylesterase	↓
Lactonase	↓
- Paragh et al. 2002 (n=110)70
Paraoxonase	↓
- Dantoine et al. 2002 (n=334)71
Paraoxonase	↔	↔

↑ : PON1 activity level was significantly higher in patients compared to controls; ↔ : PON1 activity level did not significantly differ between patients and controls

^*The examined population sample also included patients with other forms of dementia